BreezeMeds — A $199 GLP-1 With 4 Named Pharmacy Partners & the Lion MD Medical Team (2026 Review)

BreezeMeds's structural position in the 2026 U.S. telehealth GLP-1 weight-loss category is editorially distinctive in two specific dimensions: verifiable named-physician disclosure with publicly searchable NPI numbers, and multi-pharmacy partner transparency with published contact information for each. The Lion MD medical team — Dr. Ana Lisa Carr MD (NPI: 1689841744) and Dr. Kelly Tenbrink MD (NPI: 1346482684) — is named directly in BreezeMeds's published FAQ, and both physician NPIs can be independently verified in seconds at the U.S. National Provider Identifier Registry. Publishing physician NPIs publicly is rare in U.S. telehealth GLP-1 — most platforms describe providers generically as "board-certified U.S. physicians" without giving buyers a path to verify the individual prescribing clinician's licensure. The four named compounding pharmacy partners (Belmar Pharmacy, Strive Pharmacy, Epiq Scripts, Casa Pharma Rx) — each with a published phone number — provide multiple verification paths via state pharmacy boards. Multi-pharmacy partner disclosure is editorially rare in the compounded GLP-1 category; most platforms either don't name pharmacy partners or name only one. BreezeMeds's four-partner disclosure is a stronger transparency signal than most.

The Lion MD medical team — verifiable NPIs explained

BreezeMeds publishes its medical team identity directly in its FAQ:

"Lion MD: A trusted team of nationwide medical professionals led by Dr. Ana Lisa Carr MD (NPI: 1689841744) and Dr. Kelly Tenbrink MD (NPI: 1346482684)."

An NPI — National Provider Identifier — is a unique 10-digit identifier issued by the Centers for Medicare & Medicaid Services (CMS) to every U.S. healthcare provider. NPIs are publicly searchable in the NPI Registry. Publishing physician NPIs publicly is editorially distinctive because it gives buyers:

• Verifiable physician identity — confirm Dr. Carr and Dr. Tenbrink are real, licensed, currently-practicing physicians.
• State license verification path — NPI lookups surface the state and license details that buyers can cross-reference with state medical boards.
• Specialty and practice verification — NPI records include taxonomy codes that identify the physician's clinical specialty.
• Practice history — NPI registrations have timestamp data that confirm operating tenure.

Compared to other named-medical-leadership platforms in our 14-platform 2026 review set:

• JRNYS: Dr. Henry Legere (Columbia + Harvard) — named, no NPI published
• MyStart Health: Dr. Ritu Chopra (Beverly Hills MD) — named, no NPI published
• Tuyo Health: Dr. German Echeverry — named CEO, no NPI published
• Fella Health: 3-advisor panel — named, no NPIs published
• BreezeMeds: Dr. Carr (NPI 1689841744) and Dr. Tenbrink (NPI 1346482684) — named WITH verifiable NPIs

BreezeMeds is the only platform in our 2026 review set that publishes both physician names AND their verifiable NPI numbers — a level of editorial transparency that meaningfully simplifies buyer due-diligence.

Four named compounding pharmacy partners — why it matters

BreezeMeds publishes four compounding pharmacy partners with phone numbers and URLs:

Multi-pharmacy partner disclosure with published contact information is editorially rare in the compounded GLP-1 category. Comparable named-pharmacy disclosures in our 2026 review set:

• HealthRX.com: One named pharmacy — Manifest Pharmacy (Greer SC, Section 503A & USP-797)
• ReflexMD: Named partners (PCAB+ACHC-accredited)
• BreezeMeds: Four named pharmacy partners with published phone numbers — broadest published partner-network disclosure

The structural advantage of multi-pharmacy partner disclosure: buyers can verify each pharmacy's state licensure separately, and BreezeMeds presumably routes prescriptions based on patient state and pharmacy availability. The structural editorial gap: BreezeMeds doesn't surface PCAB or ACHC accreditation status alongside the named partners — ReflexMD does. Buyers should verify each pharmacy's accreditation directly before purchase if pharmacy quality controls are a primary concern.

BreezeMeds pricing in 2026

BreezeMeds publishes two prominent starting prices: $199/month GLP-1 Weight Loss Injections and $169/month NAD+ Injections. Here's how that positions BreezeMeds in our 14-platform 2026 review set:

At $199/month, BreezeMeds is priced as a premium-disclosure option — buyers are paying $100-110/mo more than the JRNYS / bmiMD / HealthRX.com price floor in exchange for the verifiable-NPI named medical team and four-partner pharmacy disclosure. Whether that trade-off is editorially worthwhile depends on how much you value pre-purchase provider and pharmacy verification.

Medications BreezeMeds offers

BreezeMeds publishes two prominent product categories:

• Weight Loss Injections — From $199/month. Compounded GLP-1 medications (semaglutide and/or tirzepatide, specific tier breakdown confirmed during consultation). Fulfilled by one of the four named compounding pharmacy partners.
• NAD+ Injections — From $169/month. Adjacent product line for energy and metabolic support.

Note: BreezeMeds does not prominently offer FDA-approved branded medications (Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda) on its landing pages. If you want branded options on the same platform, see JRNYS, Measured, Tuyo Health, Helimeds, or FuturHealth.

Are BreezeMeds medications compounded or FDA-approved?

BreezeMeds's GLP-1 medications are compounded — prepared by one of four named compounding pharmacy partners (Belmar, Strive, Epiq Scripts, Casa Pharma Rx). Compounded products are not individually FDA-approved as finished drug products (category-wide caveat). The four pharmacy partners operate under Section 503A of the FD&C Act when compounding patient-specific prescriptions.

BreezeMeds GLP-1 side effects

Side effects are the same as any GLP-1 medication. Standard FDA-mandated safety considerations apply:

• Boxed warning: Thyroid C-cell tumor risk; do not use if you or family member has history of MTC or MEN 2 syndrome.
• Serious side effects requiring monitoring: Acute pancreatitis, diabetic retinopathy complications, hypoglycemia, acute kidney injury, serious allergic reactions, acute gallbladder disease, increase in heart rate, suicidal behavior and ideation monitoring.
• Common side effects: Nausea, vomiting, diarrhea, stomach pain, constipation — particularly during titration weeks 1-4.

Who BreezeMeds is best for

BreezeMeds is a strong fit if you:

• Value verifiable named-physician disclosure — Dr. Carr's NPI 1689841744 and Dr. Tenbrink's NPI 1346482684 can be independently confirmed in seconds
• Want multi-pharmacy partner transparency — four named compounding pharmacies with published phone numbers
• Appreciate full LegitScript certification (seal 47653984)
• Want a 50,000+ patient base with sustained operating presence
• Need FSA/HSA eligibility
• Want all-50-state service
• Value NAD+ injections at $169/month as an adjacent product
• Want a platform with a verifiable Delaware LLC + Marietta GA HQ for institutional accountability
• Are willing to pay $199/month (above the JRNYS/bmiMD/HealthRX.com floor) for the editorial transparency premium

BreezeMeds is not the best fit if you:

• Need the absolute lowest published starting price — JRNYS $89, bmiMD $99, HealthRX.com $99 all beat BreezeMeds's $199
• Want FDA-approved branded medications on the same platform
• Need faster intake-to-medication timeline (BreezeMeds publishes 2-3 weeks vs HealthRX.com 3-4 days, JRNYS 5-7 days)
• Want pharmacy partner accreditation (PCAB, ACHC) surfaced alongside the named partners (see ReflexMD)
• Want a concrete money-back weight-loss outcome guarantee (see Clinic Secret's 6/12-month tiered guarantee)
• Are pregnant, nursing, under 18, or have GLP-1 contraindications

Real-world BreezeMeds patient feedback

BreezeMeds publishes a 5-star rating displayed prominently on the landing page with a "Join 50,000+ BreezeMeds patients" headline. The 50,000+ patient base is meaningful editorial scale — comparable to Helimeds, FeelGood, MyStart Health, and ReflexMD in the patient-base tier of our review set.

For independent sentiment, buyers should:

• Search Better Business Bureau for "Breezemeds" complaints, resolution rates, and disclosed feedback
• Check Reddit communities r/glp1 and r/loseit for patient experience threads
• Verify pharmacy partner ratings via state pharmacy board databases
• Search Trustpilot for additional sentiment

BreezeMeds is the only platform in our 14-platform 2026 review set that publishes both named physician identities AND their verifiable NPI numbers (Dr. Carr 1689841744, Dr. Tenbrink 1346482684), alongside four named compounding pharmacy partners with published phone numbers. That dual disclosure is editorially rare — even if the $199/month starting price is meaningfully above the lower-cost compounded tier.— Bartley Editorial Analysis

BreezeMeds vs alternatives

BreezeMeds's structural position: the strongest combination of verifiable named-physician disclosure (NPI numbers) AND multi-pharmacy partner transparency in our 14-platform 2026 review set. The trade-off is the $199/month starting price, meaningfully above the disclosure-and-low-price combinations at JRNYS and HealthRX.com.

BreezeMeds pros and cons

BreezeMeds sign-up & ongoing-care checklists

BreezeMeds frequently asked questions

Honest verdict — should you choose BreezeMeds?

BreezeMeds earns its 4.0/5 editor's rating on a structurally distinctive combination of verifiable named-physician disclosure (Dr. Carr NPI 1689841744 and Dr. Tenbrink NPI 1346482684) and multi-pharmacy partner transparency (four named partners with published phone numbers). This dual disclosure is editorially the rarest medical-team-plus-pharmacy combination in our 14-platform 2026 review set. The verifiable NPI disclosure simplifies pre-purchase physician due diligence to seconds; the four-pharmacy partner disclosure provides multiple state-board verification paths and operational resilience against single-pharmacy supply disruption.

What pulls the rating below the JRNYS / HealthRX.com 4.6 ceiling is straightforward: $199/month starting price is meaningfully above the $89-$99 cash-pay floor at JRNYS, bmiMD, and HealthRX.com. The 2-3 week intake-to-medication timeline is slower than the 3-4 day timeline at HealthRX.com and Clinic Secret. Tirzepatide-vs-semaglutide tier breakdown isn't granularly published. Pharmacy partner accreditation (PCAB, ACHC) isn't surfaced alongside the named partners. And FDA-approved branded medications aren't offered.

The bottom line

If you specifically value verifiable named-physician disclosure with NPI numbers AND multi-pharmacy partner transparency with published contact information, BreezeMeds is the editorially strongest combination of those two specific signals in our 14-platform 2026 review set — and the $199/month premium over the JRNYS / bmiMD floor reflects the disclosure depth. If you prioritize absolute lowest cash-pay cost, JRNYS at $89, bmiMD at $99, or HealthRX.com at $99 all beat BreezeMeds by $100+/mo. If you need faster intake-to-medication timeline, those same platforms — particularly HealthRX.com (3-4 days) and Clinic Secret (3 days) — are materially faster. If you want FDA-approved branded medications, JRNYS, Measured, Tuyo Health, Helimeds, and FuturHealth all offer them.

Published: June 3, 2026 · Last updated: June 3, 2026 · Verified: June 2026 · Spot a factual issue? Tell our editors.